Adjuvant radiotherapy delays recurrence following subtotal resection of spinal cord ependymomas

Michael C. Oh, Michael E. Ivan, Matthew Z. Sun, Gurvinder Kaur, Michael Safaee, Joseph M. Kim, Eli T. Sayegh, Derick Aranda, and Andrew T. Parsa


Background. Ependymoma is the most common glial tumor of the adult spinal cord. Current consensus recommends surgical resection with gross total resection (GTR) whenever possible. We performed a comprehensive review of the literature to evaluate whether adjuvant radiotherapy after subtotal resection (STR) has any benefit.

Methods. A PubMed search was performed to identify adult patients with spinal cord ependymoma who underwent surgical resection. Only patients who had clearly defined extent of resection with or without adjuvant radiotherapy were included for analysis. Kaplan-Meier and multivariate Cox regression survival analyses were performed to determine the effects of adjuvant radiotherapy on progression-free survival (PFS) and overall survival (OS).

Results. A total of 348 patients underwent surgical resection of spinal cord ependymomas, where GTR was obtained in 77.0% (268/348) of patients. Among those who received STR, 58.8% (47/80) received adjuvant radiotherapy. PFS was significantly prolonged among those who received adjuvant radiotherapy after STR (log rank; P < .001). This prolonged PFS with adjuvant radiotherapy remained significant in multivariate Cox regression analysis (STR versus STR + RT group; hazard ratio (HR) = 2.26, P = .047). By contrast, improved OS was only associated with GTR (GTR versus STR + RT group; HR = 0.07, P = .001) and benign ependymomas (HR = 0.16, P = .001).

Conclusions. Surgery remains the mainstay treatment for spinal cord ependymomas, where GTR provides optimal outcomes with longest PFS and OS. Adjuvant radiotherapy prolongs PFS after STR significantly, and OS is improved by GTR and benign tumor grade only.

Keywords: ependymoma, extent of resection, radiotherapy, recurrence, spinal cord, spine.

Spinal cord ependymomas are the most common intramedullary glial tumors in adults.1–7 A large population-based cancer registry (Surveillance, Epidemiology, and End Results study) has reported that ependymomas are more common in the spinal cord than in intracranial regions across all age groups (36.2% spine, 22.2% infratentorial, and 11.8% supratentorial), occurring more often in males (56.9%).8 Although spinal cord ependymomas generally have better prognosis than do other intramedullary glial tumors,3,9 factors affecting prognosis have not been clearly defined. Some studies indicate that older age and spinal cord tumor independently had better survival rates, compared with younger age and intracranial tumor (either supratentorial or infratentorial), respectively,10 although a consensus in prognostic factors has not been reached. Further studies identifying factors important for improving outcomes are critical to improve clinical management and prognosis. Ideally, an optimal treatment paradigm for an individual patient should be defined based on tumor features, such as histology, tumor location, radiographic findings, and presenting symptoms to provide optimal progression-free survival (PFS) and overall survival (OS).

Factors that have been shown previously to affect prognosis are tumor grade,11–13 tumor size,14 length of clinical history,15 preoperative neurological status,16 presence of distant metastasis,17 adjuvant radiotherapy,14,18–22 and extent of resection.1,23–27 Among these factors, extent of resection with gross total resection (GTR) seems to be the most consistent variable in predicting improved OS and PFS, whereas others remain controversial.3,7,28 Of importance, advancements in...
microsurgical techniques have allowed en bloc GTR over piecemeal subtotal resection (STR) as the standard of care for spinal cord ependymomas, despite a variety of complications associated with surgery. When GTR is not possible, however, because of infiltration into surrounding spinal cord or nerve roots, many authors have recommended adjuvant radiotherapy.

Despite general recommendations supporting the role of adjuvant radiotherapy, there are controversies. For example, some studies failed to show significant improvement in postoperative outcomes with added morbidity associated with radiation. To help clarify this controversy, we performed a comprehensive review of the literature on patients with classic spinal cord ependymoma (World Health Organization [WHO] grade II and III) who underwent surgical resection to determine whether adjuvant radiotherapy improves tumor control.

**Materials and Methods**

**Article Selection**

A comprehensive systematic review of the English-language literature was performed. An integrative analysis was performed, in which individual patient data from studies were pooled and statistically analyzed. Aggregated data sets, in which individual patient data were grouped, were not included in this analysis because the goal of the study was to analyze the individual patient data with long follow-up periods to allow analysis of PFS and OS with use of Kaplan-Meier and Cox regression survival analyses. Articles were identified via PubMed search using the key word “ependymoma;” this resulted in 3765 articles published from 1965 through 2011. All articles were individually reviewed to identify patients with surgical spinal cord ependymoma in which the extent of resection (GTR vs. STR) was clearly identifiable. We initially identified 80 articles with a total of 425 patients who underwent surgical resection to determine whether adjuvant radiotherapy improves tumor control.

**Data Extraction**

Data from case reports and institutional series were extracted with the following information: age, sex, extent of resection (GTR vs. STR), adjuvant radiotherapy, morbidity, recurrence or progression of disease, time to recurrence or progression of disease, mortality, time to mortality, and duration of follow-up. Treatment paradigms were stratified into 4 groups: GTR, GTR + RT, STR, or STR + RT. Survival analyses were performed for GTR, STR, and GTR + RT groups because the main goal of the study was to determine the role of adjuvant radiotherapy in patients receiving STR. Patients who underwent biopsy or surgery with chemotherapy were excluded.

**Statistical Analysis**

PFS and OS were analyzed using building Kaplan-Meier curves, and differences were assessed using log rank or Tarone-Ware (when curves cross each other) test. This analysis was followed by Cox proportional hazards analysis by backward stepwise model selection to adjust for confounding variables including age, sex, extent of resection, tumor grade (WHO II vs. III), morbidity, tumor location (upper: cervicomedullary to cervicothoracic; lower: thoracic, lumbar, and conus), and radiation treatment. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated. Continuous variables were analyzed using the t test or analysis of variance with post hoc Tukey test, and categorical values were analyzed using the Pearson’s χ² test. Fisher’s exact test was used if the expected cell count in a contingency table was <5. P < .05 was considered to be statistically significant. Analyses were performed using the statistical software package SPSS, version 20 (SPSS).

**Results**

**Clinical Characteristics**

The literature search yielded a total of 68 manuscripts with a total of 348 patients who underwent surgical treatment for classic spinal cord ependymomas with clearly identifiable extent of resection. The mean age was 41.0 years with a range of 18–73 years, and there were more males (57.6%) than females (42.4%) overall (Table 1).

Of 348 patients, 268 (77.0%) received GTR, and the remaining 80 (23.0%) received STR. In the STR group, 47 (58.8%) of 80 received adjuvant RT, and only 10 (3.7%) of 268 received adjuvant radiotherapy after GTR. We grouped tumors into benign (WHO grade II) or anaplastic (WHO grade III) ependymomas. Overall, 11 (3.4%) of 319 tumors were anaplastic. The number of anaplastic ependymomas differed significantly across treatment paradigms with significantly more anaplastic tumors in the STR groups (8 [11.3%] of 71), compared with the GTR groups (3 [1.2%] of 248; P < .001) (Table 1). Moreover, ependymomas in the lower spinal cord had significantly lower GTR rate (67.2%, 88 of 131), compared with the tumors in the upper spinal cord (83.0%, 180 of 217; P < .001).

**Adjuvant RT Improves PFS after STR**

We first performed Kaplan-Meier analysis to determine whether adjuvant radiotherapy had a significant effect
Table 1. Demographic characteristics of patients who underwent surgical resection for spinal cord ependymomas

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>GTR</th>
<th>GTR + RT</th>
<th>STR</th>
<th>STR + RT</th>
<th>(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(N)</td>
<td>258</td>
<td>10</td>
<td>33</td>
<td>47</td>
<td>.176(^a)</td>
</tr>
<tr>
<td>Mean age ± SEM</td>
<td>41.9 ± 0.8</td>
<td>39.0 ± 4.2</td>
<td>39.7 ± 2.6</td>
<td>37.2 ± 2.2</td>
<td>.99</td>
</tr>
<tr>
<td>Gender (male)</td>
<td>56.4%</td>
<td>62.5%</td>
<td>58.1%</td>
<td>63.2%</td>
<td>.874(^b)</td>
</tr>
<tr>
<td>Anaplastic ependymomas</td>
<td>0.8% (2/238)</td>
<td>10% (1/10)</td>
<td>13.3% (4/30)</td>
<td>9.8% (4/41)</td>
<td>&lt;.001(^c)</td>
</tr>
<tr>
<td>Location of tumor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper</td>
<td>68.6% (177/258)</td>
<td>30% (3/10)</td>
<td>42.4% (14/33)</td>
<td>48.9% (23/47)</td>
<td></td>
</tr>
<tr>
<td>Lower</td>
<td>31.4% (81/258)</td>
<td>70% (7/10)</td>
<td>57.6% (19/33)</td>
<td>51.1% (24/47)</td>
<td>&lt;.001(^b)</td>
</tr>
</tbody>
</table>

Mean age and gender did not differ across different treatment paradigms, while number of anaplastic ependymomas and location of tumors, broadly divided into upper and lower spinal cord, were significantly different across different treatment paradigms.

\(^a\)Analysis of variance.

\(^b\)\(X^2\) test.

\(^c\)Fisher’s exact.

It was clear from our analysis that GTR provided the best PFS and OS (log rank, \(P < .001\); Fig. 1 and 2). Of importance, adjuvant RT significantly prolonged PFS in the STR group. The median survival time (50% PFS) was 48 months in the STR group, which was doubled to 96 months with adjuvant radiotherapy in the STR + RT group. Because of lack of sufficient events, median survival times could not be calculated for the GTR group. Five-year PFS rates for GTR, STR + RT, and STR groups were 97.9%, 65.3%, and 45.1%, respectively, with 20.2% improvement in PFS with adjuvant RT after STR. In contrast to PFS, adjuvant radiotherapy did not improve OS significantly in patients who received STR (pairwise Tarone-Ware, \(P = .643\)). Five-year OS for GTR, STR + RT, and STR groups was 98.8%, 79.3%, and 73.7%, respectively.

Our previous analysis, however, revealed that the grades of tumors were significantly different across different treatment paradigms (Table 1); this could be responsible for the differences found in Kaplan-Meier analysis. Thus, we performed multivariate Cox proportional hazards analysis to determine whether adjuvant RT prolongs PFS after STR while accounting for other confounding variables, including age, sex, extent of resection, grade of tumor (WHO II vs III), morbidity, and tumor location. We found that different treatment paradigms resulted in significant difference in PFS (Table 2). Of most importance, STR alone had an HR of 2.26 (95% CI = 1.01–5.07; \(P = .047\)), compared with STR + RT. Consistent with the Kaplan-Meier analysis, GTR provided the best PFS outcomes, with HR of 0.06 (95% CI = 0.02–0.23; \(P < .001\)), compared with STR + RT. Furthermore, tumor grade remained significant in the analysis, with anaplastic WHO grade III tumors having HR of 2.88 (95% CI = 1.13–7.34; \(P = .026\)), compared with benign WHO grade II tumors. Other variables did not remain significant and were dropped from the analysis.

We then performed the same multivariate Cox regression analysis for OS while accounting for the same confounding variables (Table 3). In contrast to PFS, there were no significant improvements in OS with adjuvant RT after STR (STR: HR 1.01, \(P = .99\), when compared with STR + RT). Best OS outcomes were achieved with GTR (HR 0.07, \(P = .001\), 95% CI = 0.02–0.36, when compared with STR + RT). Tumor grade was again found to be a significant variable, with anaplastic tumors having HR of 6.08 (95% CI = 2.01–18.37; \(P = .001\)), compared with benign tumors. As before, other variables did not remain significant and were dropped from the analysis.

**Radiation Dose Does Not Affect Recurrence or Survival**

There is some evidence that total dose of radiotherapy may influence clinical outcomes in patients with spinal cord ependymomas who undergo STR.\(^{30}\) A study by Shaw et al., for example, used a median dose of 50 Gy, with a range of 36–57 Gy, and suggested that total dose >50 Gy may be superior.\(^{3,30}\) Thus, we stratified
the patients treated with adjuvant RT into 2 groups: those treated with $< 50$ Gy ($40.7 \pm 2.2$ Gy; range, 20–48.6; $n = 16$) and those treated with $\geq 50$ Gy ($51.8 \pm 0.5$ Gy; range, 50–60 Gy; $n = 24$) of total radiation. The dose of radiation given was available for 40 patients, with 16 patients receiving $< 50$ Gy and the remaining 24 patients receiving $\geq 50$ Gy of total radiation. Overall, there were 6 recurrences in the $< 50$ Gy group (37.5%) and 10 in the $\geq 50$ Gy group (41.7%). We again constructed Kaplan-Meier curves, which showed that there were no significant differences between the 2 groups in PFS ($P = .559$) or OS ($P = .510$; Fig. 3A and B). Moreover, radiation dose did not remain as a significant variable in multivariate Cox regression analysis while accounting for other important confounding variables, such as extent of resection and tumor grade (data not shown).

### Table 2. Multivariate Cox proportional hazards analysis of PFS

<table>
<thead>
<tr>
<th>Variable</th>
<th>HR</th>
<th>95% CI</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>STR + RT</td>
<td>1</td>
<td>1.00–1.00</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>GTR</td>
<td>0.06</td>
<td>0.02–0.23</td>
<td>.001</td>
</tr>
<tr>
<td>STR</td>
<td>2.26</td>
<td>1.01–5.07</td>
<td>.047</td>
</tr>
<tr>
<td>WHO grade III</td>
<td>2.88</td>
<td>1.13–7.34</td>
<td>.026</td>
</tr>
</tbody>
</table>

We performed backward stepwise model selection to determine the PFS benefit of adjuvant radiation treatment in patients who received STR while accounting for age, gender, extent of resection, tumor grade (WHO grade II vs. III), morbidity, and tumor location (upper: cervicomedullary to cervicothoracic, lower: thoracic, lumbar, and conus). We used STR + RT groups as the control for comparison. Only treatment paradigms and tumor grade remained significant in the analysis, with significantly improved PFS in the STR + RT group compared to STR group.

### Table 3. Multivariate Cox proportional hazards analysis of OS

<table>
<thead>
<tr>
<th>Variable</th>
<th>HR</th>
<th>95% CI</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>STR + RT</td>
<td>1</td>
<td>1.00–1.00</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>GTR</td>
<td>0.07</td>
<td>0.02–0.36</td>
<td>.001</td>
</tr>
<tr>
<td>STR</td>
<td>1.01</td>
<td>0.33–3.03</td>
<td>.99</td>
</tr>
<tr>
<td>WHO grade III</td>
<td>6.08</td>
<td>2.01–18.37</td>
<td>.001</td>
</tr>
</tbody>
</table>

We performed backward stepwise model selection to determine the OS benefit of adjuvant radiation treatment in the STR group while accounting for age, gender, extent of resection, tumor grade (WHO grade II vs. III), morbidity, and tumor location (upper: cervicomedullary to cervicothoracic, lower: thoracic, lumbar, and conus). Similar to PFS, only treatment paradigms and tumor grade remained significant in the analysis, but only GTR remained as the beneficial variable for improving OS with no improvement with adjuvant radiotherapy in the STR groups.

Although adjuvant RT is routinely given by most providers after STR of spinal cord ependymomas, the benefit with respect to prolonging PFS and OS is controversial.\textsuperscript{14,18,19,21,22,31} Moreover, the recommended
dose of radiation has not been clearly defined because high doses of radiation may be associated with increased risk of radiation myelopathy. Thus, we performed a comprehensive review of the literature by performing an integrative analysis (in which the previously reported individual cases are pooled and analyzed) to determine whether adjuvant RT can prolong PFS in patients with spinal cord ependymoma, specifically focusing on those who received STR.

Our results indicate that 77.0% of patients with spinal cord ependymoma who undergo surgical resection received a GTR. This treatment paradigm provides the best outcomes in terms of both PFS and OS (Fig. 1 and 2), which is consistent with previous reports. Five-year PFS and OS rates were 97.9% and 98.8%, respectively, in our study, suggesting that GTR can provide a definitive cure in most cases. Thus, GTR should be the goal of every spinal cord ependymoma surgery if significant neurological morbidity can be avoided.

Spinal cord ependymomas that are subtotally resected tend to recur at rates up to 50%–70% without adjuvant therapy, which is consistent with the findings in our current study. Five-year recurrence rate after STR was 54.9%, with 5-year survival rate of 73.7% in this study. This high recurrence rate has promoted the use of adjuvant RT for patients receiving STR, although without clear evidence supporting improved outcomes. For example, a study by Celi et al. showed that postoperative RT did not affect outcomes in patients with filum terminale ependymomas. By contrast, a study by a group at the MD Anderson Cancer Center found favorable outcomes with adjuvant RT for myxopapillary ependymomas, which most often occur in the filum terminale. A study by Abdel-Wahab et al. found that adjuvant RT prolonged PFS in a univariate analysis of tumor and extent of resection. Thus, in this report, we performed a Kaplan-Meier and Cox regression survival analyses on patients with previously reported spinal cord ependymoma to determine whether adjuvant RT improves tumor control after STR.

Overall, our analysis showed a significantly prolonged PFS with adjuvant RT after STR. Five-year PFS was improved by 20.2% from 45.1% in the STR group to 65.3% in the STR + RT group. Because these results may have been confounded by the higher percentage of anaplastic ependymomas in the STR group (13.3%), compared with the STR + RT group (9.8%), we performed multivariate Cox regression analysis to account for other confounding variables, including tumor grade. This analysis confirmed prolonged PFS with adjuvant RT after STR in our dataset.

Surprisingly, OS among patients receiving STR was not affected by adjuvant RT. This could be attributable to the benign nature of the majority of spinal cord ependymomas with low mortality rates. Moreover, it was difficult to discern the true etiology of mortality in these patients on the basis of their description in the literature. It is possible that patients die more often of complications related to their disease (such as neurological deficits, immobility, deep venous thrombosis, and infections) and not directly due to disease recurrence. If such were the case, one would not expect to see similar correlations between PFS and OS, which may be partly responsible for the variable beneficial results for PFS and OS with adjuvant RT in the STR group.

The optimal dose of radiation for subtotally resected spinal cord ependymomas also still remains to be determined. A study by Shaw et al. found that 6 (35%) of 7 patients who received ≤50 Gy postoperative RT recurred, and only 1 (20%) of 5 recurred after receiving >50 Gy. Thus, they recommended delivering a total dose of 55 Gy, regardless of extent of surgery. In our study, however, we found no difference in outcomes for PFS and OS based on radiation dose, in both univariate and multivariate analyses. However, it is likely that there are many other confounding variables, such as whole spine versus local radiation, tumor grade, and histology, which may affect outcomes. Further studies are needed to delineate the effects of these variables. Most authors currently recommend doses of 45–54 Gy with long-term follow-up because recurrence can occur many years after initial treatment.

Because this is a retrospective integrative analysis of pooled individual patient data from multiple studies, there are clear inherent limitations involved with this method. Studies in general may be more likely to only report cases with good outcomes, and thus, our results may be biased toward better outcomes than in reality. Furthermore, the differences in patient treatment at different institutions, such as surgeon’s experience, whether adjuvant RT is used, follow-up protocol, and protocols involving treatment of recurrent tumors, were not taken into account and may have affected results presented in this study. Specifically, individual patient data used in this study may not completely reflect the patients with spinal cord ependymoma as a whole. Because aggregated patient data (where individual patient data are grouped) were not used in this study, our results can be biased by individual case reports or smaller studies presented by institutions with a relatively less experience in treating patients with spinal cord ependymomas. Although our study did not include some large studies that did not report individual patient data, a number of publications used in our study contained cohorts of patients >20 from authors with significant experience with spinal cord ependymoma surgery.

Our results, thus, could represent the sum of results achieved at large referral centers to small institutions with relatively fewer experiences with spinal cord ependymomas and may not represent similar results obtained at busy institutions with large volumes of patients with spinal cord ependymoma. Overall, our findings would be best confirmed in a prospectively randomized trial conducted at multiple institutions with the capacity to treat spinal cord
ependymomas with use of both surgical resection and adjuvant RT.

In summary, our results indicate that adjuvant RT can prolong PFS in patients with spinal cord ependymoma who receive STR, and OS is only improved by GTR and benign tumor grade. GTR provides optimal outcomes with longest PFS and OS, and thus, GTR should be the main goal of every spinal cord ependymoma surgery. When STR is the best achievable surgical outcome, adjuvant RT should be strongly considered with careful long-term follow-up.

**Conclusion**

Our results show that best outcomes for spinal cord ependymomas are achieved with GTR, which is consistent with previous findings. Moreover, adjuvant RT can prolong PFS among patients who receive STR. Although adjuvant RT may not ultimately affect OS, decreasing recurrence can appreciably benefit patient outcomes by avoiding repeated surgeries, which are associated with significant morbidities. Prolonged surveillance is recommended, regardless of extent of surgery or adjuvant therapies because recurrence can occur many years after surgical resection of spinal cord ependymomas.

**Acknowledgments**

Conflict of interest statement. None declared.

**Funding**

This work was supported by National Research Service Award from the National Institutes of Health (F32NS073326-01 to M. C. O.) and Reza and Georgianna Khatib Endowed Chair in Skull Base Tumor Surgery (to A.T. P.).

**References**


